PNPLA6-related Disorder With Expanded Phenotype Including Parkinsonism, Dystonia, And Abnormal Dopamine Transporter Imaging
Objective: To present a case of PNPLA6-related disorder with an expanded phenotype. Background: PNPLA6-related are autosomal recessive disorders with heterogeneous clusters of cerebellar ataxia, upper…Alpha-synuclein DNA methylation in CD45+ blood cells in Parkinson’s disease
Objective: We examined the methylation status of the DNA SNCA-intron1 at CD45+ blood cells in patients with sporadic Parkinson's disease (PD). Background: PD is a…Long term safety of levodopa/carbidopa infusion with ND0612: Results from a phase 2b, international, open-label study
Objective: The primary objective of this long-term study was to evaluate the safety and tolerability of a 24-hour regimen and a 16-hour ‘waking day’ regimen…Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease
Objective: To study the effect of COMT inhibitors (opicapone and entacapone) in Parkinson's disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) and an insufficient control of…Motor- and Non-motor Symptoms in Patients Treated with 24-hour Daily Levodopa-Carbidopa Intestinal Gel Infusion: Analysis of the COSMOS Observational Study
Objective: Describe and compare demographic and clinical characteristics, motor, and non-motor symptoms for patients with advanced Parkinson’s disease (APD) by daily duration (<24 hours or…Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
Objective: Our investigation aimed to explore interhemispheric functional alterations and its corresponding morphological synchronization changes. Background: Levodopa-induced dyskinesias are common motor complication of Parkinson’s disease…Rapid on-time onset and sustained improvements in motor states throughout the day following treatment with levodopa/carbidopa intestinal gel (LCIG) vs immediate-release levodopa/carbidopa oral capsules (LCIR)
Objective: To assess the speed of on-time onset and characterize the patterns of motor states throughout the day in advanced Parkinson’s disease patients treated with…Gut Microbiote Distinctive Features and Microbiota-Metabolome Profile in Parkinson’s Disease: Focus on Levodopa and LCIG
Objective: The aim of this work was to study the microbiome of PD patients, studying the effect of dopaminergic drugs mainly focusing on the effect…Levodopa Challenge Test for Prediction of Deep Brain Stimulation Efficacy on Motor Functions for Parkinson’s Disease
Objective: To investigate the correlation between pre-operative response to levodopa following levodopa challenge test and the efficacy of deep brain stimulation (DBS) on motor functions…Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study
Objective: To evaluate the effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease who had previously undergone deep brain stimulation (DBS). Background:…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 57
- Next Page »